| Title: | Design and baseline characteristics of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Study |
Authors: | Sillesen, Henrik
Albers, Gregory
Altafullah, Irfan
Benavente, Oscar
Book, Diane
Broderick, Joseph
Calder, Christopher
Callahan, Alfred S.
Carlini, Walter
Chaturvedi, Seemant
Chippendale, Thomas
Clark, Wayne
Collins, Greg
Coull, Bruce
Davis, Patricia
Devlin, Thomas
Dick, Arthur R.
Dirr-Ledbetter, Lucy Younger
Dooneief, George
Duff, R. Scott
Estronza, Nordeli
Forteza, Alejandro
Frankel, Michael R.
Frey, James L.
Friday, Gary
Goldstein, Jerome
Goldstein, Steven
Graham, Gleen
Harper, Wayne
Harris, Jonathan
Hendin, Barry
Hess, David C.
Hinton, Richard
Hollander, Joshua
Hsu, Chung Y.
Hughes, Richard L.
Kasner, Scott
Kent, T. A.
Kim, Lance
Kirshner, Howard
LaMonte, Marian
Levin, Kenneth
Libman, Richard
McDowell, Paul
McGee, Francis E.
Meyer, Brett
Minagar, Alireza
Munschauer, Frederick E.
Munson, Richard
Nash, Marshall
Orr, Sean C.
Ratinov, Gerald
Salanga, Virgilio
Sen, Souvik
Silliman, Scott
Singer, Richard
Smith, Don
Sullivan, Herman
Thaler, David
Tietjen, Gretchen
Tuchman, Michael
Uskavitch, David
Verro, Piero
Vicari, Ralph
Weinstein, Richard
Wilterdink, Janet
Zweifler, Richard
Beaudry, Michael
Cote, Robert
Hoyte, Keith
Lebrun, Louise Helene
Norris, John
Selchen, Daniel
Shuaib, Ashfaq
Simard, Denis
Spence, David
Teal, Philip
Winger, Michael
Schmidt, Reinhold
Pramsohler, Bruno
Schmidauer, Christoph
Kaste, Markku
Sivenius, Juhani
Wagner, Anna
Terent, Andreas
Amarenco, Pierre
Milandre, Loic
Chollet, Francois
de Broucker, Thomas
Moulin, Thierry
Roullet, Etienne
Leys, Didier
Mahagne, Marie Helene
Hennerici, Michael
Heiss, W. D.
Busse, Otto
Haberl, Roman
Harms, L.
Diener, C.
Hamann, G. |
UNESCO Clasification: | 32 Ciencias médicas
3205 Medicina interna |
Keywords: | Cholesterol levels
Double-Blind Method
Heptanoic Acids
Atorvastatin
Hydroxymethylglutaryl-CoA Reductase Inhibitors |
Issue Date: | 2003 |
Journal: | Cerebrovascular Diseases |
Abstract: | Evidence suggests that statin therapy reduces the risk of stroke in patients with coronary heart disease (CHD), but its benefit for patients with cerebrovascular disease and no history of CHD remains uncertain. The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Study is a prospective, multi-centre, double-blind, randomised, placebo-controlled trial designed to evaluate the effects of atorvastatin 80 mg/day in patients who previously experienced a stroke or transient ischaemic attack, but who have no known CHD. A total of 4,732 patients have been enrolled, and the data collection phase of the study is expected to be completed by October 2004. SPARCL is the first study primarily designed to prospectively evaluate the effect of statin treatment in secondary stroke prevention. |
URI: | http://hdl.handle.net/10553/52035 |
ISSN: | 1015-9770 |
DOI: | 10.1159/000072562 |
Source: | Cerebrovascular Diseases[ISSN 1015-9770],v. 16, p. 389-395 (Diciembre 2003) |
| Appears in Collections: | Artículos
|
